What Is ASP and How Is It Tracked for Lipitor?
ASP stands for Average Sales Price, a Medicare reimbursement benchmark for Part B drugs calculated quarterly from manufacturers' sales data. Lipitor (atorvastatin), a statin for cholesterol, was mainly oral for retail/outpatient use, not Part B injectables, so official CMS ASP data doesn't apply. Trends are instead derived from commercial sources tracking net prices or wholesaler acquisition costs (WAC), which correlate closely with ASP-like metrics.
Lipitor's Price Trend Since Generic Entry
Lipitor's brand peaked at ~$4 per pill in 2011 before generics launched (November 2011). Brand ASP-equivalent prices fell >90% within months:
- 2011 (pre-generic): $3.50–$4.20 per 20mg pill.
- 2012: Dropped to $0.20–$0.50.
- 2013–2015: Stabilized at $0.10–$0.30.
- 2020s: Generic atorvastatin now $0.05–$0.15 per pill (GoodRx/WAC data), with minimal brand sales [1].
No recent brand ASP upticks; generics dominate 99%+ of market.
Why Did Prices Drop So Sharply?
Patent expiry (U.S. Patent 5,273,995 expired November 2011) triggered generic competition from 17+ ANDA filers (Teva, Ranbaxy, Mylan). FDA tentative approvals accelerated entry despite litigation. Volume shifted to generics overnight, collapsing brand revenue from $5B+ peak to <$100M by 2013 [2].
Current Generic Atorvastatin Pricing and Variations
| Strength | WAC per Pill (2024) | GoodRx Cash Price (30-day supply) |
|----------|---------------------|-----------------------------------|
| 10mg | $0.08 | $4–$8 |
| 20mg | $0.12 | $6–$12 |
| 40mg | $0.15 | $8–$15 |
| 80mg | $0.20 | $10–$20 | [3]
Prices vary by pharmacy, insurer, and coupons; Medicare Part D averages $10–$20 monthly.
Factors Influencing Recent Trends
- Inflationary pressures: Generic WAC rose 5–10% yearly post-2020 due to manufacturing costs, but competition caps hikes.
- Shortages: Intermittent atorvastatin shortages (e.g., 2022–2023) caused 20–30% temporary spikes [4].
- No brand revival: Pfizer discontinued most U.S. brand Lipitor doses by 2017.
Patent Status and Future Competition
Core patents expired 2011; no active U.S. Orange Book patents remain for Lipitor [5]. Exclusivity ended long ago, blocking new barriers. Generic market stable with 20+ suppliers.
[1]: FDA Orange Book
[2]: Pfizer Annual Reports
[3]: GoodRx Atorvastatin Pricing
[4]: FDA Drug Shortages Database
[5]: DrugPatentWatch.com - Lipitor Patents